Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Trial of PXD101 in Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas
2007-001396-11Phase 2Completed
- Sponsor
- CuraGen Corporation
- Start
- May 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of belinostat in cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL), sponsored by CuraGen Corporation. Primary endpoint: Objective response or stable disease rate. Started May 2007; status: completed.
02
Drugs
belinostat
03
Conditions
cutaneous T-cell lymphoma (CTCL)peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on 2007-001396-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001396-11.